Axon Enterprise (NASDAQ:AXON) Hits New 1-Year High at $391.00

Shares of Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) hit a new 52-week high during trading on Thursday . The stock traded as high as $391.00 and last traded at $385.93, with a volume of 32337 shares. The stock had previously closed at $383.01.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AXON shares. JMP Securities increased their price target on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an "outperform" rating in a report on Thursday, September 12th. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 10th. Craig Hallum lifted their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Bank of America began coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $400.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Axon Enterprise presently has an average rating of "Moderate Buy" and an average price target of $365.38.

Axon Enterprise Price Performance

The company's 50-day moving average is $344.06 and its 200-day moving average is $316.19. The firm has a market cap of $29.45 billion, a price-to-earnings ratio of 113.96, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same quarter last year, the business posted $0.80 EPS. The company's revenue was up 34.5% compared to the same quarter last year. Equities research analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, Director Michael Garnreiter sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Michael Garnreiter sold 1,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the transaction, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now directly owns 98,825 shares of the company's stock, valued at approximately $37,449,733.75. The disclosure for this sale can be found here. Insiders have sold a total of 317,981 shares of company stock worth $115,662,734 over the last 90 days. Insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dorsey Wright & Associates boosted its stake in shares of Axon Enterprise by 0.3% during the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company's stock valued at $4,135,000 after purchasing an additional 39 shares in the last quarter. Avantax Advisory Services Inc. boosted its position in Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company's stock worth $1,659,000 after buying an additional 40 shares during the period. Brookstone Capital Management grew its holdings in Axon Enterprise by 5.1% during the 1st quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company's stock worth $263,000 after acquiring an additional 41 shares during the last quarter. CWM LLC increased its position in Axon Enterprise by 1.5% in the 2nd quarter. CWM LLC now owns 2,820 shares of the biotechnology company's stock valued at $830,000 after acquiring an additional 43 shares during the period. Finally, Wealthspan Partners LLC raised its stake in shares of Axon Enterprise by 4.9% during the second quarter. Wealthspan Partners LLC now owns 965 shares of the biotechnology company's stock valued at $284,000 after acquiring an additional 45 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.